News | February 02, 2026
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
